Fasudil (2HCl), 100 mg

Rho-associated coiled-coil kinase (ROCK) inhibitor supplied as the dihydrochloride salt (Fasudil 2HCl) in a 100 mg vial. The compound selectively targets the catalytic domains of ROCK1 and ROCK2, suppressing downstream phosphorylation of myosin light chain phosphatase and LIM kinase to modulate actin stress fiber formation and smooth muscle contraction. Supplied by STEMCELL Technologies as a research-grade small molecule, the powder is readily soluble in DMSO at ≥50 mg/mL and in aqueous buffers once warmed. Stock solutions are aliquoted and stored at -20 °C, protected from light, and thawed immediately before use to minimize freeze-thaw degradation.

Investigators deploy this reagent across in vitro cell culture assays and in vivo rodent models examining pulmonary arterial hypertension, cerebral ischemia-reperfusion injury, cardiac fibrosis, spinal cord injury, and amyloid-induced neurotoxicity. Working concentrations for cell-based studies generally fall between 1 µM and 30 µM, while systemic dosing in animal studies commonly ranges from 5 mg/kg to 100 mg/kg delivered by intraperitoneal injection. The product is intended for research use only and supports pharmacology, stem cell differentiation, and tissue regeneration studies investigating ROCK-mediated signaling.